Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

OTHER 7INDUSTRY 3OTHER_GOV 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Classical hematology 1

Conditions

Vaso-Occlusive Crises 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Anemia, Sickle Cell 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Glutamine × Clear all
NCT01179217 2020-08-19

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Emmaus Medical, Inc.

Phase 3 Completed
230 enrolled 19 charts 1 FDA
Classical hematology

Vaso-Occlusive Crises, Anemia, Sickle Cell

NCT01087658 2013-06-21

GLUTOX

Sanofi

Phase 3 Completed
200 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00455247 2013-06-05

Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects

Société des Produits Nestlé (SPN)

Phase 3 Completed
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡